Most Recent
The litigation funder that backed a recently settled shareholder class action against the directors of collapsed mining company CuDeco and KPMG will seek a 35 per cent cut from the settlement.
ASIC has raised the prospect of criminal charges linked to the Shield Master Fund, after bringing civil penalty proceedings alleging up to $530 million in retirement savings was used for unauthorised purposes.
A judge has approved a $120 million settlement in a class action against AMP that followed the banking royal commission, saying while it was a “very disappointing outcome” for group members it was still fair and reasonable.
Construction PRO
Investors in Falcon Capital's First Guardian Master Fund will recover less than 10 per cent of a $33.5 million loan advanced to an inexperienced Melbourne developer, under a settlement reached by the company's liquidators.
Investors in Falcon Capital's First Guardian Master Fund will recover less than 10 per cent of a $33.5 million loan advanced to an inexperienced Melbourne developer, under a settlement reached by the company's liquidators.
Former Keystone Asset Management director and developer Paul Chiodo will have to produce bank records for himself and family members, after a judge shot down his appeal of a ruling ordering production.
The corporate regulator is seeking penalty and disqualification orders against a financial adviser whose businesses allegedly earned $37 million for spruiking the collapsed First Guardian fund, a court has heard.
Nuix has lost its appeal of a ruling that found it must pay $20 million in legal costs before its insurers must cover its bills for defending multiple class actions and an ASIC case over its $1.8 billion float.
Construction PRO
An activist group can't block the owners of Claravale Station from clearing almost 3,000 hectares of savanna in the Northern Territory, with a judge finding it would be difficult to prove the government’s decision was legally unreasonable.
A class action against Johnson & Johnson over alleged ineffective cold medicine has attacked the pharmaceutical company’s application for soft class closure, telling a court the process would produce useless data and only need to be repeated.